PVR and breast cancer: BC patients with low expression of CD155 had 10-year DFS and OS rates of 70.37% and 80.64%, respectively, which were significantly higher than those with high expression of CD155 (58.81% for DFS, p = 0.033; 58.24% for OS, p = 0.002, Figure 2).